Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Combined With DOS as Neoadjuvant Therapy for Gastric and GEJ Adenocarcinoma
NCT07776639Phase 2Active, not recruiting
- Start
- May 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma. Started May 2026; status: active, not recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07776639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07776639.